Parkinson disease is the second most common neurodegenerative disease. Pain is the frequent non-motor symptom that significantly compromises the quality of life, affecting 80% of patients during the course of the disease. There is currently no evidence-based treatment for PD-related pain in general. Nociceptive pain is the most frequent pain in PD an is frequently musculoskeletal in nature. Epidural spinal cord stimulation is known to provide analgesic effects in several types of pain syndromes. Here we test analgesic effects of a non-invasive trans-spinal magnetic stimulation as an add-on treatment for nociceptive (musculoskeletal) pain directly related to Parkinson disease.
Background: pain is frequent non-motor symptom in Parkinson's disease (PD) that significantly compromises the quality of life, affecting 80% of patients during the course of the disease. Nociceptive pain is the most frequent subtype, mainly musculoskeletal in nature. There is currently no evidence-based treatment for PD-related pain in general. The present study tests the effectiveness and safety of non-invasive trans-spinal magnetic stimulation (TsMS) to treat musculoskeletal pain directly related to PD in a sham-controlled randomized approach. Patients and Methods: this is a randomized, sham-controlled trial including 40 subjects, aged between 18 and 85 years, with musculoskeletal pain directly related to PD, that will be randomized to receive TsMS active or TsMS sham in a 1:1 ratio. Enrollment will take place at the Pain Center of the University of São Paulo and Movement Disorders Center of the University of São Paulo. We have decided to perform an interim analysis when 24 patients will be included in the trial in order to assess safety and calculate effect size of the active intervention, after meeting with the research and statistical board. A decision will thereafter be made to, either: 1: halt the study due to futility, 2: continue the study with a new target sample size based on the calculations made with the effect from the n= 24 sample. Expected results: the study hypothesis is that non-invasive trans-spinal magnetic stimulation is superior to sham and it is safe to use that device in patients with nociceptive (musculoskeletal) pain in PD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
27
Patients undergoing real TsMS with coil
Patients undergoing placebo TsMS with coil
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
Number of responders
Number of individuals presenting 50% pain intensity reduction (on VNS 0-10 average pain of BPI item 5) in the active vs the sham group at the last (8th week) assessment compared to baseline values.
Time frame: base line (moment of inclusion) and the last day of the patient assessment (2x in two months)
Change in baseline of Pain
Assessing by score derivated of Parkinson's Disease Pain Classification System (PD-PCS). This score range from 0 (minimum) to 90 (maximum), being considered an effective improvement in the patient's pain when the pain decreases at least in 50% from the basal score.
Time frame: base line (moment of inclusion) and in the last day after the final session of TMS-e (2x in two months)
Incidence of Treatment-Emergent Adverse Events
The safety of trans-spinal magnetic stimulation (TsMS) will be assessed by measuring the number of participants who experience serious events. Each serious adverse event be described in detail
Time frame: Immediately after the intervention (session of stimulation)
Mood
Assess mood by hospital anxiety and depression scale
Time frame: base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months)
Quality of life related to pain relief
Assess by EuroQol- 5 Dimension
Time frame: base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months)
Parkinson's disease motor symptoms
Assess by UPDRS part III
Time frame: base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months)
Interference in daily activities
measured by brief pain inventory
Time frame: base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months)
Global impression of change
Assess % of very much and much improved
Time frame: base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.